69 results about "Thrombolysis" patented technology

The invention provides a clinical diagnosis and treatment path generation method and system for tracking a chest pain patient. Wherein a dynamic spatio-temporal data atlas is constructed by synchronously collecting respiratory rhythm phase difference, coronary artery calcification integral and hypersensitive troponin curve slope, and risk degree transition signals are generated by coupling analysis of ST segment elevation amplitude asymmetric growth, left ventricular ejection fraction attenuation gradient and B-type natriuretic peptide release rate. In the acute stage, the constraint relation between a vascular recanalization time window and thrombolysis taboo is dynamically bound, in the subacute stage, a phase synchronization rule for enhancing CT scanning and anticoagulant drug dosage is established through a multidisciplinary interface, intravascular ultrasonic plaque morphological mutation characteristics and extracorporeal circulation parameters are fused, the blood supply reconstruction time sequence is dynamically adjusted based on a myocardial oxygen consumption balance equation, and the thrombolysis time sequence is determined. And path self-optimization is realized through space-time superposition of an interventional therapy delay parameter and a drug metabolism curve. According to the technical scheme provided by the invention, chest pain diagnosis and treatment path dynamic optimization and multi-modal parameter collaborative decision-making are realized, and the risk layering precision and the treatment timeliness are improved.

The invention discloses a plasmin lumbrukinase peptide dietary therapy formula suitable for rehabilitation of cardiovascular and cerebrovascular diseases, blood circulation promoting, blood stasis removing, thrombolysis, collateral dredging and microcirculation improving, and relates to the technical field of medicine and food homology dietary therapy. Soybean protein isolate and earthworm protein are used as core thrombolytic active raw materials, isomaltooligosacharide, xylitol, German Jilida collagen peptide, soybean peptide powder, Belgian imported inulin, red yeast rice and natto powder are compounded, microcrystalline cellulose and magnesium stearate are used as auxiliary materials, and probiotics / metabiotics strains such as rhamnolactobacilli JYLR-005 and the like can be selectively added. The raw materials have a synergistic effect through precise matching, plasmin and lumbrukinase peptide in earthworm protein can directly dissolve thrombus fibrin, natto powder and red yeast rice assist in lowering lipid and dissolving thrombus, multiple active peptides and prebiotics regulate intestinal microecology to improve microcirculation of the whole body, probiotics / metabiotics further strengthen the metabolic capacity of the body, no chemical medicine is added in the whole process, and the traditional Chinese medicine composition is free of toxic and side effects and free of toxic and side effects. The safety is high; the dietary therapy composition can achieve postoperative rehabilitation conditioning of cardiovascular and cerebrovascular diseases through daily consumption, effectively promote blood circulation to remove blood stasis, dissolve thrombus and dredge collaterals, improve microcirculation and relieve various discomfort caused by blood vessel clogging, raw materials are easy to obtain, compatibility is scientific, and the dietary therapy composition is suitable for large-scale production and popularization.

The invention discloses a resection device, and relates to the technical field of medical instruments. The excision device comprises a catheter, a cutting assembly and a recycling assembly, the cutting assembly and the recycling assembly are arranged at the far end of the catheter, the recycling assembly comprises a suction part and a flushing part, the suction part is at least partially connected to the far end of the catheter and provided with at least one suction opening used for adsorbing a target object, and the flushing part is connected to the far end of the suction part and provided with at least one suction opening used for adsorbing the target object. And at least one spraying opening for spraying flushing fluid is formed. The excision device is provided with the recycling assembly, flushing fluid is sprayed through the flushing part of the recycling assembly to conduct thrombolysis, meanwhile, thrombus is recycled through the suction part, the risk that the thrombus falls off and blocks a far-end blood vessel is reduced, and therefore the possibility of occurrence of far-end embolism complications is reduced; and the resection device can be used for resection of plaques with mixed lesions.

The invention relates to a mesenchymal stem cell-nano knapsack system, preparation thereof and application of the mesenchymal stem cell-nano knapsack system in treatment of cerebral arterial thrombosis. The invention constructs an engineered mesenchymal stem cell-thrombin responsive nano knapsack for sequential targeted delivery of rtPA, antioxidant active molecules and MSCs for ischemic stroke treatment. In a sequential delivery mode, firstly, a thrombus site is targeted, the thrombin is responded to release rtPA for thrombolysis, brain blood supply is recovered, and the rtPA thrombolysis efficiency is improved. The antioxidant active molecules are entrapped on the erythrocyte membrane bionic nanoparticles, are loaded on the surfaces of the MSCs in a knapsack form, penetrate through BBB and tend to damage ischemic penumbra and release the antioxidant active molecules by means of central transport and inflammatory homing effects of the MSCs, on one hand, oxidative stress is inhibited, a microenvironment beneficial to activity maintenance is provided for the MSCs, and on the other hand, the antioxidant active molecules are released; and meanwhile, the medicine cooperates with MSCs to play a role in protecting injured nerve and blood vessel units, so that the treatment effect on cerebral arterial thrombosis is improved.

To provide plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated PAI-1.SOLUTION: The disclosure includes, but is not limited to, the use of such compounds to prevent or reduce thrombosis and fibrosis, to promote thrombolysis, and to modulate lipid metabolism and treat diseases or disorders associated with elevated PAI-1, cholesterol, or lipid levels.SELECTED DRAWING: None

The invention provides a metal manganese complex, a metal manganese nano platform, a preparation method and application, and belongs to the technical field of chemical synthesis and biomedicine. The structural formula of the manganese complex is shown as a formula I. The method comprises the following steps: dropwise adding a MnCl2 aqueous solution into a THF solution containing Ce6, quickly stirring, carrying out ultrasonic treatment, and sufficiently aging to obtain preliminary Mn-Ce6NPs; and the Mn-Ce6NPs obtained in the first step is subjected to dialysis and centrifugation, and the metal manganese complex Mn-Ce6NPs is obtained. The nanoparticles have excellent chemiluminescence performance, and can specifically recognize the position of a suppository block. The prepared nanoparticles have a photodynamic and photo-thermal combined thrombolysis effect, and have an anti-oxidation function after thrombolysis, so that the purpose of treating ischemic stroke is achieved.

The invention provides a composition for improving the thrombolysis capacity of a human body, a preparation method and application thereof.The composition is prepared from, by weight, 5-30 parts of earthworm protein, 30-120 parts of hippophae rhamnoides total flavone extract, 50-150 parts of silymarin extract, 20-80 parts of maltodextrin and 15-60 parts of pregelatinized starch, the earthworm protein activates a fibrinolytic system to promote t-PA to release and dissolve thrombus, and the hippophae rhamnoides total flavone extract activates the fibrinolytic system to promote t-PA to release and dissolve thrombus; the hippophae rhamnoides total flavonoids regulate the ratio of PGI2 / TXA2 to inhibit platelet aggregation and reduce blood fat, the silymarin protects the liver function to enhance LDL-C metabolism clearing, the hippophae rhamnoides total flavonoids, the silymarin and the hippophae rhamnoides total flavonoids cooperate to form a thrombolysis-antithrombosis-metabolism regulation three-dimensional intervention system, a whole-course low-temperature mixing direct tabletting process is adopted

This invention relates to a pharmaceutical composition and its application for treating acute ischemic stroke. The pharmaceutical composition for treating acute ischemic stroke comprises separately packaged tissue-type plasminogen activator citPA5 and a platelet aggregation inhibitor. Its beneficial effects include significantly improving cerebral blood flow recovery, shortening thrombolysis time, reducing infarct volume, and improving neurological function without increasing the risk of bleeding, demonstrating a good synergistic thrombolytic effect.

This invention discloses a carrier-free, self-driven nanorobot empowered by nitric oxide, its preparation method, and its applications, belonging to the field of biomedical technology. This invention involves forming a hybrid nanoassembly by driving a nitric oxide donor drug and a photothermal photosensitizer molecule through non-covalent interactions. The surface of the hybrid co-assembled nanoassembly is modified with one or both of polyethylene glycol (PEG) modifiers and PEG thrombofibrin-targeting peptides. The molar ratio of the nitric oxide donor drug to the photothermal photosensitizer molecule is 1:10 to 10:1. The preparation method of this invention is stable, convenient, simple, and practical. The resulting thrombotargeting, nitric oxide donor drug, and photothermal photosensitizer hybrid nanoassembly exhibits extremely high drug loading capacity, enabling efficient co-loading of the hybrid nanoassembly and efficient photothermal-nitric oxide thrombolysis. This provides a novel and efficient drug delivery strategy for the treatment of cerebrovascular diseases such as thrombosis and ischemic stroke.

Provided herein are plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated PAI-1. The disclosure includes, but is not limited to, the use of such compounds to prevent or reduce thrombosis and fibrosis, to promote thrombolysis, and to modulate lipid metabolism and treat diseases or disorders associated with elevated PAI-1, cholesterol, or lipid levels.

The invention discloses a traditional Chinese medicine composition for treating and preventing cardiovascular and cerebrovascular diseases and postoperative repair and recuperation based on classic famous prescription, and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The composition is prepared by combining a prescription based on coptis and colla corii asini decoction, cassia twig decoction, cinnamomum cassia and aconitum carmichaeli decoction and poria cocos, cinnamomum cassia and aconitum carmichaeli decoction, as well as poria cocos, cinnamomum cassia and aconitum carmichaeli decoction, and poria cocos and aconitum carmichaeli decoction, and poria cocos and aconitum carmichaeli decoction, and poria cocos and aconitum carmichaeli decoction, and poria cocos and aconitum carmichaeli decoction and poria cocos and In the formula, ligusticum wallichii and earthworm promote blood circulation to remove blood stasis, dredge collaterals and dissolve thrombus; hawthorn and lotus leaf are used for dissolving turbidity, lowering lipid and regulating blood fat and cholesterol; the poria cocos and the rhizoma alismatis are used for clearing damp and promoting diuresis. The whole formula has the effects of warming yang, dredging collaterals, nourishing yin and blood, promoting blood circulation to remove blood stasis, dissolving turbidity, reducing lipid, calming the heart, soothing the nerves and the like, can be used for treating cardiovascular and cerebrovascular diseases, conditioning dyslipidemia, preventing atherosclerosis and postoperative repair and nursing at the same time, is wide in application range and high in safety, can be prepared into various oral dosage forms, and has a good application prospect.

The application discloses a sports nutrition food composition for blood vessel health and post-exercise recovery. Each 40g contains soybean protein isolate, whey protein, resistant dextrin, inulin, ginkgo biloba extract, hawthorn extract, grape seed extract, sea buckthorn peptide, natto powder (containing natto kinase), coenzyme Q10, natural vitamin E, vitamin C, bacillus subtilis DE111 and mineral probiotic premix. The application realizes blood vessel cleaning and post-exercise recovery through the synergy of multiple pathways such as direct thrombolytic effect of natto kinase, anti-platelet aggregation of ginkgo biloba / hawthorn / grape seed, protection of blood vessel endothelium by coenzyme Q10 / VE / VC, and regulation of intestinal tract by bacillus subtilis DE111. In-vitro thrombolysis experiment shows that the composition has clear fibrinolytic activity. All components meet the national standard of sports nutrition food, are safe and compliant, and are suitable for people with thrombosis risk and people who need blood vessel repair after high-intensity exercise.

The utility model relates to a thrombolysis catheter which comprises an outer catheter provided with a main body tube, the far end side of the main body tube is provided with a perfusion section, and the perfusion section is provided with a plurality of perfusion holes arranged at intervals in the axial direction; the inner pushing pipe is provided with a pipe body, and the pipe body is arranged in the main body pipe in a sliding and penetrating mode so as to selectively cover at least part of the perfusion holes and further adjust the effective length of the perfusion section; the core rod is arranged in the inner push tube and the outer guide tube in a sliding and penetrating manner; the plugging device comprises a capturing part located on the far-end side and a plugging part located on the near-end side, the capturing part and the plugging part are connected with each other, and the far end of the core rod is fixedly connected with the near end of the plugging part. The thrombolysis catheter can capture thrombus falling from the blood vessel wall, and is simple to operate and high in thrombus removal efficiency.

A product, composition, suspension and / or method to dissolve vaso-occlusive clots in vivo in a sickle diseased subject utilizing Target-specific Thrombolytic Urokinase Spheres (TTUS). The TTUS can target vaso-occlusive clots in vivo and then lyse the obstructive blood clots with high efficiency can be intravenously administered to a subject in need thereof. The TTUS are configured to dissolve vaso-occlusive clots by converting plasminogen in blood of the subject into plasmin molecules that dissolves the clot. The nanospheres can encapsulate an enzymatically active bioreactive agent, such as urokinase. Since the active enzyme is targeting and binding essentially only to obstructive clots, there is minimal risk of side-effects to the subject. The nanospheres are less than one micron in diameter, resulting in a size much smaller than red blood cells.

Provided herein are plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated PAI-1. The disclosure includes, but is not limited to, the use of such compounds to prevent or reduce thrombosis and fibrosis, to promote thrombolysis, and to modulate lipid metabolism and treat diseases or disorders associated with elevated PAI-1, cholesterol, or lipid levels. 20 24 20 26 17 22 A pr 2 02 4 A B S T R A C T 2 0 2 4 2 0 2 6 1 7 2 2 A p r 2 0 2 4

The utility model discloses a thrombolysis catheter fixing device, relates to the technical field of medical instruments, and solves the problem that a device capable of accommodating and fixing an exposed thrombolysis catheter in the catheter thrombolysis process is lacked in the prior art. The thrombolysis catheter fixing band comprises a fixing band body, connecting assemblies matched with each other are arranged at the two ends of the fixing band body, a fixing assembly used for containing a thrombolysis catheter coil is arranged above the fixing band body, the fixing assembly is hollow, and at least two notches used for a catheter to pass through are reserved in the fixing assembly. According to the purpose, the fixing band is wound and bound to the foot or the four limbs punctured with the thrombolysis catheter through the connecting assembly, the portion, provided with the fixing assembly, of the fixing band is rotated and adjusted to be aligned with the puncture point, the hollow fixing assembly facilitates storage of a catheter coil in the fixing assembly, and notches in the fixing assembly facilitate passing of the two ends of the catheter; by means of the arrangement, the catheter ring can be completely contained inside, the whole catheter ring cannot shake along with movement of a patient, and the treatment comfort of the patient is improved.

A double-balloon thrombolysis and thrombectomy device, comprising a catheter, an access sheath, and a hemostasis valve. The catheter comprises a base, a body, a first balloon, and a second balloon, the first balloon and the second balloon are sleeved over the body, the first balloon is located at a distal end of the body, and the second balloon is located at the proximal end of the first balloon; the base is connected to the proximal end of the body, and comprises a main connection port, a first connection port and a second connection port; the first balloon is connected to the first connection port, and the second balloon is connected to the second connection port; the surface of the second balloon is provided with a plurality of micropores; and the access sheath is sleeved over the catheter body, and connected to the catheter body through the hemostasis valve.

The present disclosure provides use of icaritin in preparing a drug for preventing and treating a bleeding disorder and belongs to the field of medicine. The icaritin can relieve platelet dysfunction, shorten thromboplastin time, and promote blood coagulation, and can be used for preventing and treating the bleeding disorder, especially for treating hemorrhagic transformation after cerebral infarction, gastrointestinal bleeding caused by a thrombolytic or antithrombotic drug for cerebral infarction, or a bleeding complication of a thrombolytic or antithrombotic drug for myocardial infarction.

Provided herein are methods for safe and effective thrombolysis in therapy for human subjects with symptoms of a potential stroke or acute myocardial infarction (“AMI”) using a sequential administration of a low dose bolus of human tissue plasminogen activator (“tPA”) followed by an infusion of a mutant form of human pro-urokinase (“proUK”).

The embodiment of the invention discloses an evaluation method for an in-vitro hypotonic thrombolysis effect and application of the evaluation method. The method comprises: providing a first blood clot; mixing the second blood clot with hypotonic saline water, standing, and collecting the second blood clot; the thrombolysis effect is evaluated by comparing the performance differences between the first blood clots and the second blood clots. The change condition of blood plaque dissolution under the hypotonic condition is explored, and an experimental platform is laid for establishing a new plaque dissolution method. The method provided by the invention is high in operability and has a good application prospect.

The invention relates to a pharmaceutical composition with an effect of improving blood-brain barrier injury after cerebral infarction thrombolysis. The pharmaceutical composition is prepared from the following raw material medicines in parts by weight: 1-100 parts of astragaloside, 0.25-25 parts of tanshinol and 1-100 parts of notoginsenoside R1.

Hemorrhage and vascular instability can be induced by thrombolytic and anti-coagulant therapies. Presented herein, in certain aspects, are methods for the treatment and / or prevention of hemorrhage and vascular instability that comprise administering a compound disclosed herein to a subject in need thereof.

The present invention identifies the phenotype of abnormal aggregation of smarca5 mutant red blood cells, and studies the development, cell morphology, number and other characteristics of corresponding erythroid cells and myeloid cells in smarca5 mutants. It partially analyzes the mechanism of smarca5 regulating the phenotype of red blood cell aggregation, thereby constructs a fluorescent thrombus zebrafish model, establishes a venous thromboembolism disease model, and provides a method, use and drug for preventing red blood cell aggregation, or anti-thrombosis, or promoting thrombolysis, or reducing thrombosis formation in a subject, with a view to being used as a thromboembolism disease model for drug screening, which has clinical guiding significance.

This invention discloses a traditional Chinese medicine (TCM) for treating neck, back, and leg pain, as well as cardiovascular and cerebrovascular diseases, and its preparation method, belonging to the field of TCM technology. The TCM is composed of various medicinal herbs, including peach kernel, safflower, angelica, red peony root, leech, and earthworm, in specific weight proportions. Its core treatment principle is "activating blood circulation and removing blood stasis, clearing the meridians, promoting qi circulation and relieving pain, and dissolving thrombi and unblocking collaterals," while also addressing the symptoms by tonifying qi and blood and nourishing the liver and kidneys. The herbs work synergistically to treat both the root cause and the symptoms. The preparation method includes steps such as raw material screening and processing, ingredient mixing, decoction extraction, secondary decoction, flavoring, and packaging and storage. The process is simple and low-cost. This TCM has definite efficacy and few side effects, effectively treating injuries from falls and blows, lumbar muscle strain, lumbar disc herniation, cerebral infarction, cerebral hemorrhage, and myocardial infarction. It also improves symptoms such as limb numbness and hemiplegia, solving the problems of limited treatment scope and unstable efficacy in existing TCM formulas, making it suitable for clinical application.

To provide an ultrasound-assisted thrombolysis device.SOLUTION: An ultrasound-assisted thrombolysis device 100 includes a catheter 110, a first ultrasound module 120, a second ultrasound module 130, and a control device 140. The first ultrasound module 120 and the second ultrasound module 130 are installed in the catheter 110 and electrically connected to the control device 140. The first ultrasound module 120 is used to emit ultrasound toward a thrombus to dissolve the thrombus, and the second ultrasound module 130 is used to emit ultrasound toward the thrombus and measure a distance between the catheter 110 and the thrombus. The control device 140 controls the first ultrasound module 120 and the second ultrasound module 130 on the basis of the measured distance.SELECTED DRAWING: Figure 2

The present application relates to the field of thrombolytic catheter, in particular, to a kind of indwelling type blood-passable thrombolytic catheter, including catheter, the inside of the pipe wall of the catheter is provided with medicine cavity, the catheter is provided with medicine spraying hole being communicated with the medicine cavity, the catheter is equipped with air bag, the air bag is equipped with at least two, the air bag is spaced apart, the medicine spraying hole is located between the adjacent two air bags, the catheter is connected with the medicine delivery tube for sending medicine to the inside of the medicine cavity, the air bag is connected with air pipe, further including sheath tube, one end of the sheath tube is connected with hemostasis valve, the other end of the sheath tube is an opening;The present application aims at overcoming the deficiencies of prior art and providing a kind of indwelling type blood-passable thrombolytic catheter, when local thrombolysis is carried out to blood vessel again, it does not affect the blood transport inside blood vessel, avoid the necrosis of the inner wall cells of blood vessel due to hypoxia.

Provided herein are plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated PAI-1. The disclosure includes, but is not limited to, the use of such compounds to prevent or reduce thrombosis and fibrosis, to promote thrombolysis, and to modulate lipid metabolism and treat diseases or disorders associated with elevated PAI-1, cholesterol, or lipid levels.

The present application belongs to the technical field of medical first aid and resource scheduling, and relates to a stroke emergency green channel pre-starting and resource scheduling method and system. The method comprises: collecting multi-modal diagnosis and treatment data of a stroke patient; calculating a patient condition comprehensive score to determine the patient condition response level; generating a pre-starting instruction corresponding to the intensity; resource time window pre-occupation; synchronously starting the preparation of thrombolysis path tasks and thrombus extraction path tasks for ischemic stroke patients; generating a personalized timing table according to the reverse whole-link task completion time, triggering priority hierarchical upgrade reminders according to the overtime length; recording the whole-process data of diagnosis and treatment according to the preset personalized timing table; and generating a quality control report. Through the innovative design of hierarchical pre-starting, double-path parallel scheduling, whole-process timing control and the like, the present application greatly shortens the stroke treatment time, significantly improves the vascular recanalization rate and the neurological functional prognosis effect of the patient.

According to the tail end dynamic thrombus rotary removal equipment and the using method thereof, in the working process, under the guidance of the guide wire, the endoscopic pipeline stretches into a blood vessel to conduct thrombus removal operation, thrombus enters the tail end of the endoscopic pipeline, the activated rotary cutting blade conducts rotary cutting and smashing, the thrombus can be directly smashed and sucked out, and the thrombus can be directly removed. The problem of fragmentation residues caused by the fact that traditional suction or stent thrombus extraction can only extrude thrombus is avoided, and the thrombus extraction device is particularly suitable for stubborn thrombus rich in fibrin. The negative pressure value and the parameters of the motor module are accurately set through the touch screen, different thrombus sizes and hardness are adapted, and the defects that a time window needs to be strictly controlled and the bleeding risk exists in the thrombolysis therapy are overcome. The working face of the shaver at the tail end of the endoscopic pipeline is 1-3mm lower than the end face of the outer wall pipe, so that direct contact with the blood vessel wall is avoided; the negative pressure system sucks the chippings into the recovery tank in real time, and the risk of far-end embolism caused by traditional mechanical embolism taking is reduced.

The application discloses a kind of acute cerebral infarction thrombolysis hemorrhage patient treatment combined cold deposit intervention device, it is related to cold deposit infusion technical field, including base, cross transfer box is rotatably connected on base;It also includes infusion hard pipe, infusion hose, fixed plate, first spring, limit frame, drive assembly and fixing mechanism, the end of infusion hose with needle is placed on placement table, infusion hard pipe lower portion is connected with fixed plate, first spring is connected between fixed plate and support, first spring is wound on infusion hard pipe, infusion hard pipe upper portion is connected with limit frame, cross transfer box lower portion is provided with drive assembly, cross transfer box is equipped with the fixing mechanism for clamping and fixing blood bag.The application is first by fixed mechanism to blood bag clamping and fixing, then by drive assembly, realize blood bag automatic replacement, avoid when infusion medical staff cannot leave sickbed, cause medical staff waste, improve the operation convenience of device.